Drugs / VTP-43742
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03724292 | Aug 2015 → Mar 2016 | psoriasis | Vitae Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02555709 | Aug 2015 → Mar 2016 | psoriasis | Vitae Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VTP-43742 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03724292 ↗ |
| Known as | VIMIROGANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4172726 ↗ |
| Modality | Small molecule | — CHEMBL4172726 ↗ |
| Route | Oral | “administered as an oral capsule once daily” NCT02555709 ↗ |